VTVT RSI Chart
Last 7 days
-11.0%
Last 30 days
-4.4%
Last 90 days
181.2%
Trailing 12 Months
2957.8%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 0 | 0 | 0 | 0 |
2022 | 5.0M | 5.0M | 2.0M | 2.0M |
2021 | 5.8M | 5.2M | 4.6M | 4.0M |
2020 | 0 | 0 | 0 | 6.4M |
2019 | 11.3M | 10.6M | 7.3M | 2.8M |
2018 | 2.3M | 4.8M | 8.1M | 12.4M |
2017 | 288.0K | 119.0K | 96.0K | 291.0K |
2016 | 845.0K | 917.0K | 822.0K | 634.0K |
2015 | 1.3M | 1.0M | 776.5K | 519.0K |
2014 | 1.1M | 1.3M | 1.4M | 1.5M |
2013 | 0 | 0 | 0 | 976.0K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 05, 2024 | baker bros. advisors lp | back to issuer | - | - | -57,657 | - |
Feb 27, 2024 | akkaraju srinivas | acquired | 2,654,080 | 11.81 | 224,732 | - |
Nov 29, 2022 | fry john a | bought | 33,772 | 0.8347 | 40,461 | - |
Nov 28, 2022 | fry john a | bought | 16,969 | 0.8262 | 20,539 | - |
Dec 20, 2021 | perelman ronald o | sold | -100,050 | 1.15 | -87,000 | - |
Feb 26, 2021 | nelson rich s. | bought | 28,600 | 2.86 | 10,000 | - |
Feb 26, 2021 | nelson rich s. | bought | 143,000 | 2.86 | 50,000 | - |
Feb 26, 2021 | kozlov hersh | bought | 27,400 | 2.74 | 10,000 | - |
Dec 17, 2020 | perelman ronald o | bought | 1,000,000 | 1.6 | 625,000 | - |
Dec 10, 2020 | perelman ronald o | bought | 1,000,000 | 1.6 | 625,000 | - |
Which funds bought or sold VTVT recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 01, 2024 | CONCOURSE FINANCIAL GROUP SECURITIES, INC. | sold off | - | - | - | -% |
May 01, 2024 | BNP PARIBAS FINANCIAL MARKETS | new | - | 212 | 212 | -% |
Apr 26, 2024 | Planning Capital Management Corp | new | - | 14,707 | 14,707 | 0.01% |
Apr 24, 2024 | CENTRAL TRUST Co | new | - | 118 | 118 | -% |
Apr 15, 2024 | Sunbelt Securities, Inc. | unchanged | - | 181 | 353 | -% |
Mar 11, 2024 | VANGUARD GROUP INC | sold off | -100 | -449,139 | - | -% |
Mar 11, 2024 | VANGUARD GROUP INC | new | - | 270,469 | 270,469 | -% |
Feb 14, 2024 | BANK OF AMERICA CORP /DE/ | sold off | -100 | -180 | - | -% |
Feb 14, 2024 | Royal Bank of Canada | new | - | 6,000 | 6,000 | -% |
Feb 14, 2024 | Royal Bank of Canada | sold off | -100 | - | - | -% |
Unveiling vTv Therapeutics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
vTv Therapeutics Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 | 2017Q4 | 2017Q3 | 2017Q2 |
Revenue | -100.0% | - | 9,000 | - | 9,000 | 2,000,000 | 9,000 | 3,000,000 | 9,000 | 987,000 | 497,000 | 7,000 | 8,000 | 1,828,000 | 921,000 | 4,522,000 | 3,375,000 | 2,473,000 | 2,064,000 | 233,000 | 15,000 | 13,000 |
Operating Expenses | -25.9% | 4,707,000 | 6,352,000 | 5,689,000 | 4,036,000 | 8,481,000 | 11,118,000 | 4,603,000 | 4,679,000 | 5,267,000 | 4,569,000 | 6,395,000 | 5,433,000 | 6,620,000 | 5,208,000 | 4,873,000 | 4,856,000 | 11,331,000 | 11,198,000 | - | - | - |
S&GA Expenses | 7.6% | 2,569,000 | 2,388,000 | 2,634,000 | 1,831,000 | 5,348,000 | 5,716,000 | 2,221,000 | 2,242,000 | 2,164,000 | 2,035,000 | 1,989,000 | 1,770,000 | 2,392,000 | 2,386,000 | 2,073,000 | 2,158,000 | 2,737,000 | 2,255,000 | - | - | - |
R&D Expenses | -46.1% | 2,138,000 | 3,964,000 | 3,055,000 | 2,205,000 | 3,133,000 | 5,402,000 | 2,382,000 | 2,437,000 | 3,103,000 | 2,534,000 | 4,406,000 | 3,663,000 | 4,228,000 | 2,822,000 | 2,800,000 | 2,698,000 | 8,594,000 | 8,943,000 | - | - | - |
EBITDA Margin | -4.4% | -12.82 | -12.27 | -13.95 | -4.79 | -4.15 | -4.35 | -1.33 | -1.30 | -1.85 | -1.87 | - | - | - | - | - | - | - | - | - | - | - |
Interest Expenses | 16.7% | 7,000 | 6,000 | 8,000 | - | 1,000 | 6,000 | 6,000 | - | - | 67,000 | 283,000 | 404,000 | 514,000 | 626,000 | 743,000 | 822,000 | 870,000 | 855,000 | 852,000 | - | - |
Income Taxes | - | - | - | - | - | 200,000 | - | 100,000 | - | 15,000 | - | - | - | 100,000 | - | - | - | 200,000 | - | - | - | - |
Earnings Before Taxes | 27.1% | -4,441,000 | -6,090,000 | -5,468,000 | -4,091,000 | -9,224,000 | -9,483,000 | -1,365,000 | -841,000 | -5,927,000 | 1,607,000 | -6,882,000 | -5,960,000 | -5,014,000 | -3,982,000 | -2,328,000 | -1,961,000 | -9,396,000 | -9,960,000 | - | - | - |
EBT Margin | -4.4% | -12.87 | -12.33 | -14.01 | -4.82 | -4.17 | -4.40 | -1.42 | -1.42 | -1.99 | -2.00 | - | - | - | - | - | - | - | - | - | - | - |
Net Income | 26.7% | -3,478,000 | -4,745,000 | -4,261,000 | -3,151,000 | -7,007,000 | -7,051,000 | -1,087,000 | -608,000 | -4,241,000 | 1,126,000 | -4,399,000 | -3,608,000 | -2,882,000 | -2,155,000 | -1,091,000 | -796,000 | -3,072,000 | -2,952,000 | - | - | - |
Net Income Margin | -5.7% | -10.03 | -9.50 | -10.64 | -3.65 | -3.14 | -3.24 | -1.04 | -1.01 | -1.38 | -1.33 | - | - | - | - | - | - | - | - | - | - | - |
Free Cashflow | 57.6% | -2,914,000 | -6,880,000 | -8,827,000 | 706,000 | -1,021,000 | -6,417,000 | -3,594,000 | -3,998,000 | -5,299,000 | -2,212,000 | - | - | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Assets | -26.2% | 11.00 | 15.00 | 22.00 | 29.00 | 33.00 | 36.00 | 37.00 | 20.00 | 25.00 | 31.00 | 22.00 | 17.00 | 15.00 | 7.00 | 11.00 | 7.00 | 9.00 | 9.00 | 9.00 | 11.00 | 9.00 |
Current Assets | 5.3% | 11.00 | 10.00 | 14.00 | 21.00 | 27.00 | 29.00 | 31.00 | 14.00 | 16.00 | 22.00 | 11.00 | 9.00 | 7.00 | 4.00 | 7.00 | 4.00 | 3.00 | 4.00 | 4.00 | 5.00 | 3.00 |
Cash Equivalents | 14.7% | 9.00 | 8.00 | 13.00 | 19.00 | 12.00 | 15.00 | 18.00 | 12.00 | 13.00 | 20.00 | 11.00 | 8.00 | 6.00 | 2.00 | 6.00 | 3.00 | 4.00 | 5.00 | 4.00 | 7.00 | 4.00 |
Net PPE | -16.4% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities | 0.4% | 30.00 | 29.00 | 29.00 | 28.00 | 27.00 | 28.00 | 30.00 | 14.00 | 10.00 | 8.00 | 9.00 | 10.00 | 11.00 | 13.00 | 17.00 | 17.00 | 18.00 | 19.00 | 22.00 | 23.00 | 29.00 |
Current Liabilities | 3.3% | 11.00 | 10.00 | 9.00 | 9.00 | 8.00 | 7.00 | 10.00 | 13.00 | 8.00 | 6.00 | 5.00 | 5.00 | 6.00 | 8.00 | 11.00 | 12.00 | 13.00 | 14.00 | 17.00 | 17.00 | 19.00 |
Shareholder's Equity | -100.0% | - | 255 | 254 | 254 | 254 | 253 | 244 | 239 | 238 | 237 | 224 | 218 | 209 | 201 | 199 | 190 | 184 | 176 | 167 | 162 | 151 |
Retained Earnings | 0.1% | -281 | -281 | -280 | -274 | -265 | -267 | -253 | -247 | -248 | -259 | -273 | -274 | -290 | -253 | -268 | -252 | -233 | -223 | -217 | -220 | -233 |
Additional Paid-In Capital | 0.6% | 256 | 255 | 254 | 254 | 255 | 253 | 244 | 239 | 238 | 237 | 224 | 218 | 209 | 201 | 199 | 190 | 184 | 176 | 167 | 162 | 151 |
Shares Outstanding | -100.0% | - | 23.00 | 23.00 | 23.00 | 23.00 | 23.00 | 23.00 | 23.00 | 23.00 | 23.00 | 23.00 | 23.00 | 23.00 | - | - | - | - | - | - | - | - |
Float | - | - | - | 23.00 | - | - | - | 23.00 | - | - | - | 69.00 | - | - | - | 30.00 | - | - | - | 15.00 | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | 39.7% | -2,914 | -4,834 | -6,167 | -5,166 | -6,880 | -8,827 | 706 | -1,021 | -6,417 | -3,594 | -3,998 | -5,299 | -2,212 | -5,434 | -4,794 | -5,560 | -5,876 | -6,195 | -5,497 | -5,450 | -5,869 |
Share Based Compensation | -6.9% | 403 | 433 | 399 | 343 | 291 | 338 | 167 | 476 | 994 | 474 | 452 | 436 | 272 | 171 | 186 | 380 | 423 | 413 | 401 | 281 | 331 |
Cashflow From Investing | - | 4,404 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -68.00 | - | - | - | - |
Cashflow From Financing | -159.6% | -282 | 473 | - | 11,806 | 3,667 | 6,303 | 5,040 | -256 | 266 | 12,325 | 6,384 | 8,001 | 6,132 | 869 | 8,280 | 4,189 | 5,285 | 6,859 | 2,000 | 8,726 | 3,786 |
Consolidated Statements of Operations - USD ($) | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Revenue | $ 0 | $ 2,018,000 | $ 4,005,000 |
Operating expenses: | |||
Research and development | 13,595,000 | 12,357,000 | 13,324,000 |
General and administrative | 11,907,000 | 12,201,000 | 12,343,000 |
Total operating expenses | 25,502,000 | 24,558,000 | 25,667,000 |
Operating loss | (25,502,000) | (22,540,000) | (21,662,000) |
Other (expense) income | (1,497,000) | (3,616,000) | 2,448,000 |
Other income – related party | 574,000 | 946,000 | 1,609,000 |
Interest income | 472,000 | 352,000 | 1,000 |
Interest expense | (13,000) | (15,000) | (12,000) |
Loss before income taxes and noncontrolling interest | (25,966,000) | (24,873,000) | (17,616,000) |
Income tax provision | 0 | 200,000 | 115,000 |
Net loss before noncontrolling interest | (25,966,000) | (25,073,000) | (17,731,000) |
Less: net loss attributable to noncontrolling interest | (5,716,000) | (5,909,000) | (4,744,000) |
Net loss attributable to vTv Therapeutics Inc. | (20,250,000) | (19,164,000) | (12,987,000) |
Net loss attributable to vTv Therapeutics Inc. common shareholders | $ (20,250,000) | $ (19,164,000) | $ (12,987,000) |
Class A Common Stock | |||
Operating expenses: | |||
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic (usd per share) | $ (9.71) | $ (9.98) | $ (8.29) |
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, diluted (usd per share) | $ (9.71) | $ (9.98) | $ (8.29) |
Weighted average number of vTv Therapeutics Inc. Class A Common Stock, basic (in shares) | 2,084,973 | 1,919,788 | 1,566,204 |
Weighted average number of vTv Therapeutics Inc. Class A Common Stock, diluted (in shares) | 2,084,973 | 1,919,788 | 1,566,204 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 9,446 | $ 12,126 |
Accounts receivable, net | 102 | 173 |
Promissory note receivable | 0 | 12,243 |
Prepaid expenses and other current assets | 1,044 | 2,537 |
Current deposits | 65 | 15 |
Total current assets | 10,657 | 27,094 |
Property and equipment, net | 117 | 207 |
Operating lease right-of-use assets | 244 | 349 |
Long-term investments | 0 | 5,588 |
Total assets | 11,018 | 33,238 |
Current liabilities: | ||
Accounts payable and accrued expenses | 10,242 | 7,313 |
Current portion of operating lease liabilities | 169 | 154 |
Current portion of contract liabilities | 17 | 17 |
Current portion of notes payable | 191 | 224 |
Total current liabilities | 10,619 | 7,708 |
Contract liabilities, net of current portion | 18,669 | 18,669 |
Operating lease liabilities, net of current portion | 169 | 338 |
Warrant liability, related party | 110 | 684 |
Total liabilities | 29,567 | 27,399 |
Commitments and contingencies | ||
Redeemable noncontrolling interest | 6,131 | 16,579 |
Stockholders’ deficit: | ||
Additional paid-in capital | 256,335 | 254,757 |
Accumulated deficit | (281,042) | (265,524) |
Total stockholders’ deficit attributable to vTv Therapeutics Inc. | (24,680) | (10,740) |
Total liabilities, redeemable noncontrolling interest and stockholders’ deficit | 11,018 | 33,238 |
Class A Common Stock | ||
Stockholders’ deficit: | ||
Common stock value | 21 | 21 |
Class B Common Stock | ||
Stockholders’ deficit: | ||
Common stock value | $ 6 | $ 6 |